lobbying_activities: 2295468

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2295468	503a8908-c2e3-481b-b88e-1ead61f1a6a4	2T	RED+BLUE STRATEGIES	400693064	CIGNA CORPORATION	2019	second_quarter	HCR	Issues related to Trump Administration proposals and regulations regarding drug pricing reforms, regulations regarding rebates, and related guidances focused on affordability and accessibility to prescription medications in the United States. Proposals, guidances and call letters and impacting Medicare Part D and the role of Pharmacy Benefit Managers. Issues related to transparency in the prescription drug marketplaces including new technologies to improve physician and patient access to real time pricing questions and concerns. Issues related to utilization and access to e- prescribing tools. Issues focused on the promotion of fair competition in the prescription drug market place, including policies focused on patents, biosimilars and generic medications.	SENATE	20000		0	1	2019-05-01T15:36:02.127000-04:00